Clinical trial costs臨床試驗(yàn)成本
2011 vs. 2010 Clinical trial costs increased primarily due to higher expenses for (i) RELISTOR ($3,385), from increased clinical trial expenses including activities related to oral methylnaltrexone phase 3 study and regulatory filing fees for the submission of the sNDA for
subcutaneous RELISTOR, partially offset by decreases in expenses for Cancer ($218) and HIV ($122), all for the year ended December 31, 2011 compared to the year ended December 31, 2010.
 
2010 vs. 2009 Clinical trial costs increased primarily due to higher expenses for (i) RELISTOR ($5,224), from increased clinical trial activities for oral methylnaltrexone phase 3 study and (ii) Cancer ($352), partially offset by a decrease in expenses for HIV ($718), due to a decline in PRO 140 clinical trial activities, all for the year ended December 31, 2010 compared to the year ended December 31, 2009.
 
  
 
2011 vs. 2010 Laboratory and manufacturing supplies increased due to higher expenses for (i) RELISTOR ($1,562), primarily due to purchases of manufacturing supplies on behalf of Salix, (ii) Cancer ($166), resulting from increase in expenses for PSMA ADC, and (iii) Other projects ($199), partially offset by a decrease in HIV ($112), all for the year ended December 31, 2011 compared to the year ended December 31, 2010.
 
2010 vs. 2009 Laboratory and manufacturing supplies decreased due to lower expenses for (i) Cancer ($485), due to reduced expenses for PSMA ADC, (ii) HIV ($136), resulting from a decline in the purchases of manufacturing supplies and (iii) Other ($631), partially offset by an increase in RELISTOR ($629), due to higher expenses for the multi-dose pen, all for the year ended December 31, 2010 compared to the year ended December 31, 2009.
 
subcontractors分包商
 
2011 vs. 2010 Contract manufacturing and subcontractors decreased due to lower expenses for (i) Cancer ($288), resulting from a decline inmanufacturing expenses for PSMA ADC, (ii) RELISTOR ($2), due to lower contract manufacturing expenses for the multi-dose pen, and (iii) Other projects ($72), partially offset by increases in HIV ($222), for HIV Vaccine, all for the year ended December 31, 2011 compared to the year ended December 31, 2010.
 
2010 vs. 2009 Contract manufacturing and subcontractors decreased due to lower (i) Cancer expenses ($2,287), resulting from a decline in manufacturing expenses for PSMA ADC, (ii) Other ($962) and (iii) HIV expenses ($362), resulting from a decline in manufacturing expenses
for PRO 140, partially offset by an increase in RELISTOR expenses ($2,424), due to higher contract manufacturing expenses for the multi-dose pen, all for the year ended December 31, 2010 compared to the year ended December 31, 2009.
 
         These expenses are related to the conduct of clinical trials, including manufacture by third parties of drug materials, testing, analysis,formulation and toxicology services, and vary as the timing and level of such services are required.
   這些相關(guān)的臨床試驗(yàn)費(fèi)用，包括生產(chǎn)原料藥，測試，分析，制定和毒理學(xué)服務(wù)的第三方的行為，在不同的時(shí)間和需要多種的服務(wù)水平。
 
2011 vs. 2010 Consultants expenses de creased due to lower expenses for RELISTOR ($2,082), HIV ($41) and Other projects ($1), partially offset by an increase in Cancer ($84), all for the year ended December 31, 2011 compared to the year ended December 31, 
 
2010 vs. 2009 Consultants expenses in creased due to higher expenses for RELISTOR ($2,478) and Cancer ($41), partially offset by decreases in consultants expenses for HIV ($160) and Other projects ($56), all for the year ended December 31, 2010 compared to the year ended December 31, 2009.
   These expenses are related to the monitoring of clinical trials as well as the analysis of data from completed clinical trials and vary as the timing and level of such services are required.這些相關(guān)的臨床試驗(yàn)的監(jiān)測費(fèi)用，以及從已完成的臨床試驗(yàn)數(shù)據(jù)的分析中，完美了解到不同的階段需要的服務(wù)水平就不一樣。